Introduction Rivaroxaban is an oral anticoagulant belonging to the class of direct Factor Xa inhibitors. It is commonly prescribed for the prevention and treatment of thromboembolic disorders such as deep vein thrombosis (DVT), pulmonary embolism (PE), and stroke prevention in non-valvular atrial fibrillation. Unlike warfarin, rivaroxaban has a predictable pharmacokinetic profile and does not require … Read more
Introduction Eliquis (apixaban) is an oral direct Factor Xa inhibitor used to prevent stroke in nonvalvular atrial fibrillation and to treat or prevent deep vein thrombosis (DVT) and pulmonary embolism (PE). It binds selectively and reversibly to both free and clot-bound Factor Xa, blocking thrombin generation and fibrin clot formation without needing antithrombin III. Step-by-Step … Read more
Introduction Apixaban is a direct oral anticoagulant (DOAC) used to prevent and treat thrombosis. It is specifically indicated for stroke prevention in non-valvular atrial fibrillation, treatment and prevention of venous thromboembolism (VTE), and management of deep vein thrombosis (DVT) and pulmonary embolism (PE). Its predictable pharmacokinetics and oral administration make it a widely used alternative … Read more
